Cost effectiveness analysis of abroad and domestic pemetrexed disodium combined with cisplatin as first-line treatment in non-small cell lung cancer
LUAN Wei
GUO Shao-lai
XU Yan-ping
Abstract：Objective To analyze the cost effectiveness of abroad and domestic pemetrexed combined with cisplatin as first-line treatment in non-small cell lung cancer (NSCLC).Methods From September 2009 to July 2011,60 patients of NSCLC who were treated with pemetrexed combined with cisplatin as first-line treatment in our hospital were enrolled.Among these patients,32 ones had abroad pemetrexed disodium and 28 ones were domestic pemetrexed disodium.The cost effectiveness analysis of pharmacoeconomics was analyzed.Results The effectiveness of the two groups was 43.7％ (14/32) and 32.1％ (9/28).The ratio of cost effectiveness of the two groups was 892.40 and 724.20 respectively.Conclusion Domestic pemetrexed disodium has cost effectiveness.But compared with abroad pemetrexed disodium,domestic pemetrexed disodium has lower clinical effectiveness.
Keywords：Carcinomanon-small-cell lungCosts and Cost analysisCost effectiveness analysisPemetrexed disodium
Publication Date：2012-01-01
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)